Study Summary
This trial is testing a new drug to see if it is safe and effective against HER2-expressing solid tumors.
- Advanced Solid Tumors
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Through study completion, an average of 1 year
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Part 1 Dose escalation
1 of 2
Part 2 Indication expansion
1 of 2
Experimental Treatment
226 Total Participants · 2 Treatment Groups
Primary Treatment: SHR-A1811 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is this research initiative currently seeking participants?
"As per clinicaltrials.gov, the search for participants in this medical trial is still underway. It was first published on September 3rd 2020 with its most recent update occurring on December 22nd 2021." - Anonymous Online Contributor
How widely distributed is the trial being conducted in this metropolitan area?
"Patients can participate in this study at the Mary Crowley Cancer Research centre located in Dallas, Montefiore-Einstein Center for Cancer Care situated within Bronx, and Gabrail Cancer Research Center based out of Canton; there are 2 other sites as well." - Anonymous Online Contributor
What is the aggregate sum of participants in this trial?
"This research necessitates the recruitment of 226 qualified individuals to participate in this medical trial. Candidates can join from Mary Crowley Cancer Research (Texas) or Montefiore-Einstein Center for Cancer Care (New York)." - Anonymous Online Contributor
What dangers have been associated with utilization of SHR-A1811?
"Our assessment of SHR-A1811's safety was marked at 1, as this is a preliminary trial with limited evidence for both efficacy and safety." - Anonymous Online Contributor